Summary The transplantation of the human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HSB-2 into severe combined immunodeficient (SCID) mice was found to produce a disseminated pattern of leukaemia similar to that seen in man. The intravenous injection of 107 HSB-2 cells was associated with a universally fatal leukaemia. Histopathological examination of animals revealed the spread of leukaemia initially from bone marrow to involve all major organs including the meninges. An immunotoxin (HB2-Sap) was constructed by conjugating the anti-CD7 MAb HB2 to the ribosome-inactivating protein saporin. An in vitro protein synthesis inhibition assay revealed specific delivery of HB2-Sap immmunotoxin (IT) to CD7+ HSB-2 target cells with an IC50 of 4.5 pM. When SCID mice were injected with 106 HSB-2 cells and then treated 8 days later with a single intravenous dose of 10 Lg of immunotoxin there was a significant therapeutic effect evidenced by the numbers of animals surviving in the therapy group compared with untreated controls (X2 = 5.348, P = 0.021). These results demonstrate the useful application of human leukaemia xenografts in SCID mice and the potential therapeutic effect of an anti-CD7 immunotoxin in human T-ALL.
The ability to manipulate an accurate model of human cancer in an animal host is one way in which developments in the understanding of tumour origins, progression and treatment can be advanced. To this end much work has focused on human tumour xenografts grown in nude mice (Fogh et al., 1977; Giovanella et al., 1978) . Similarly, the nude mouse has been extensively utilised to study human leukaemia (Watanabe et al., 1978 (Watanabe et al., , 1980 , but because the resultant tumour growth manifests itself either as a solid mass or as malignant ascites this model bears little resemblance to the spectrum of disease seen in man.
The SCID mouse was first described by Bosma et al. (1983) , who reported its potential for the transplantation of allogeneic haematopoietic cells from Balb/c animals into these animals. Following this study other workers have reported the ability to engraft human lymphoid cells and stem cells to produce normal human lymphoid and myeloid differentiation in these mice (Kamel-Reid & Dick, 1988; McCune et al., 1988; Mosier et al., 1988; Mosier, 1990 ). This in turn has generated interest in the study of a murine model of AIDS using HIV-I-infected human haematopoietic cells McCune et al., 1990) . The first report of a human leukaemia cell line xenograft into SCID mice was by Kamel-Reid et al. (1989) , resulting in disseminated growth of a pre-B acute leukaemia cell line. Subsequently a range of human leukaemias of T-cell and non-T-cell origin have been demonstrated to display similar disseminated growth patterns mimicking much more closely than previous animal models the clinical picture of human leukaemia (Ghetie et al., 1990; Cesano et al., 1991; KamelReid et al., 1991; Jansen et al., 1992a; Uckun et al., 1992a) . Other tumour types including Epstein-Barr virus-associated lymphoproliferative disease (Cannon et al., 1990; Purtillo et al., 1991; Rowe et al., 1991) , T-cell lymphoma (Charley et al., 1990; Waller et al., 1991) and lung and other solid carcinomas (Reddy et al., 1987) have also been successfully engrafted into SCID mice.
In this report we describe the picture of disseminated human acute T-cell leukaemia which develops following intravenous injection of cells from the CD7+ T-ALL cell line HSB-2 into SCID mice. We describe the histological and immunohistochemical findings in tissue sections obtained from these animals. This murine model was then used to explore the in vivo therapeutic efficacy of an immunotoxin constructed with the anti-CD7 monoclonal antibody HB2 conjugated to the ribosome-inactivating protein (RIP) saporin derived from the soapwort plant Saponaria officinalis.
Materials and methods
Human acute T-cell leukaemia cell line The CD7+ T-ALL cell line HSB-2 (Adams et al., 1970) was maintained in RPMI-1640 medium containing 10% fetal calf serum (Gibco) and supplemented with 1 mmol of glutamine and 1 mmol of sodium pyruvate. Cells were maintained in the logarithmic phase of growth by passage at regular intervals. Animals SCID mice (8-10 weeks of age) were obtained from the breeding colony housed in the Biomedical Research Facility at Southampton General Hospital. Animals were housed under sterile conditions in an isolator unit and fed on autoclaved food and filter-sterilised water. Animals for experimental use were transferred from the isolator unit to microisolator filter top cages for ease of handling during experimental procedures. All experimental interventions were performed within the confines of a laminar flow hood under aseptic conditions. T-cell leukaemia inoculation HSB-2 cells were washed in RPMI and viability checked using trypan blue dye exclusion. Cells were resuspended in RPMI to a concentration whereby each animal received the same volume of inoculum (0.3 ml). Mice were injected intravenously into the lateral tail vein. Recipient animals were observed closely for signs of illness or distress (ruffled fur, weight loss, tachypnoea) and were killed in the terminal phase of their illness unless dying spontaneously. Pathology An autopsy was performed on each animal and the macroscopic findings recorded. The following tissues were removed for histological examination and fixed in 10% buffered formalin solution: liver, kidneys, lungs, heart, spleen, brain and both femurs (for bone marrow examination). Femurs were subsequently decalcified and all tissues were embedded in paraffin wax prior to sectioning and mounting.
Histology
Tissue sections were routinely stained with haematoxylin and eosin. Immunocytochemical staining was also performed on freshly cut tissue sections. A polyclonal anti-human CD3 (Dako) antibody was used to demonstrate human T-cell infiltration within decalcified femur sections and the antihuman CD43 monoclonal antibodies MT1 and DFT1 were used on the other tissue sections. A standard avidin-biotincomplex (ABC) peroxidase method for immunohistochemical staining was used and slides were counterstained with haematoxylin.
Preparation of the anti-T-cell immunotoxin HB2-Sap Monoclonal anti-CD7 antibody HB2 was obtained by injecting 1 x 107 hybridoma cells into the peritoneal cavity of pristane-primed Balb/c mice. The 7S IgG fraction of ascitic fluid was isolated by precipitation with 6 M ammonium sulphate followed by ion-exchange chromatography on DEAE-Sepharose and a further gel filtration step on Sephacryl S200 HR (Pharmacia). The single-chain ribosomeinactivating protein (RIP) saporin was purified from the seeds of Saponaria officinalis as described previously (Stirpe et al., 1983) . The conjugation of saporin to the CD7 monoclonal antibody was performed as previously described (Thorpe et al., 1985) . Briefly, both the monoclonal antibody HB2 and saporin were reacted with N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (Pharmacia) to yield 2-pyridyl disulphide-substituted products. The 2-pyridyl disulphide-substituted saporin was reduced with 50 mM dithiothreitol and the reduced product reacted for 24 h at room temperature with the substituted HB2 antibody. Immunoconjugate was separated from unreacted free saporin by gel filtration on Sephacryl S200 HR. Free unconjugated HB2 antibody was removed by cation-exchange chromatography on CM-Sepharose. The purity of the final immunotoxin product was confirmed by SDS-PAGE.
Cytotoxicity of immunotoxin in vitro
In vitro cytotoxicity of the HB2-Sap immunotoxin was assessed in a [3H]leucine incorporation assay that we have described previously (Flavell et al., 1991) . Triplicate cultures of HSB-2 cells at a density of 1 x 105 cells per well in 96-well microculture plates were exposed for 48 h at 37°C to immunotoxin or equimolar concentrations of saporin and HB2 antibody at each experimental concentration. Cells were then pulsed for 12 h with 1.0 ft Ci of [3H]leucine (TRK 510, Amersham International, UK) and finally harvested onto glassfibre filters using a Skatron cell harvester. The amount of radioactive leucine uptake by cells was measured by scintillation counting using a Packard scintillation counter. 
Establishment of human T-ALL in SCID mice
In an initial experiment eight SCID mice were inoculated with 107 HSB-2 cells intravenously. Five animals were pretreated with total body irradiation (4 Gy) immediately prior to inoculation of cells, and three animals received no irradiation. Disease spread and progression was monitored as described above. Findings described later revealed that total body irradiation was unnecessary for successful engraftment and therefore in all subsequent experiments animals were not treated with total body irradiation. Histological examination of tissue demonstrated several abnormalities listed below. Femur secretions revealed that the bone marrow morphology in diseased animals consisted of a mononuclear cell infiltrate replacing all of the normal haematological cells and ablating marrow spaces. The liver showed disseminated disease throughout the normal parenchyma. Kidney involvement was apparent as either capsular nodules or perivascular infiltration, a pattern that was similar to that seen in lung. The spleen was apparently uninvolved. Sections of brain demonstrated a meningeal infiltration of leukaemic cells with a similar pattern to the CNS infiltration seen in humans with leukaemia.
Immunohistochemical staining of tissues demonstrated the leukaemic infiltration of organs more accurately while also confirming that infiltrating cells were indeed human. Normal SCID mouse tissues demonstrated no cross-reactivity with the antibodies used. The polyclonal CD3 antibody was used on femur sections and confirmed the cellular infiltrate to be human T cell in origin (Figure la and b) . Likewise, the other organ tissue sections, when stained using the CD43 antibodies, confirmed that the leukaemic infiltrates seen in the H&E sections documented above were indeed human T-ALL in origin (Figure lc-f) .
The results from those animals that were serially sacrificed to monitor the progress of disease are shown in Figure 2 . Bone marrow infiltration was the first event to occur and could be detected as early as 7 days from the time of the initial inoculation. With the passage of time there was a progressive dissemination of the leukaemic cells such that at the stage when all the animals were dying at 6 weeks they all had multiorgan involvement. Leukaemia was universally seen in all animals given an i.v. inoculum of I07 HSB-2 cells.
The result of administering graded numbers of HSB-2 cells to SCID mice is shown in Figure 3 . There is a clear dose effect seen, with all animals given the highest cell inoculum (107) dying by 52 days (mean survival 43 days), while in animals given 104 cells per animal only one death occurred by 150 days.
In vitro cytotoxicity of HB2-Sap immunotoxin Triplicate cultures of 1 x 105 HSB-2 cells were exposed for 48 h to increasing concentrations of HB2-Sap immunotoxin (10-12 to 10i7 M). Identical cultures were set up with equimolar mixtures of saporin and HB2 antibody and with HB2 antibody alone. Cultures of untreated controls were set up with medium alone. After 48 h of exposure [3H]leucine uptake was evaluated in all cell cultures and results expressed as a percentage of the control levels, as shown in Figure 4 . An IC50 of 4.5 pM was obtained for the HB2-Sap immunotoxin, whereas the IC50 for the equimolar concentration of saporin and HB2 antibody was 0.14 JLM, representing a 31,000-fold increase in toxicity. The native HB2 antibody at all concentrations had no effect on HSB-2 cells.
Two experiments were performed in which the CD7-specific delivery of HB2-Sap immunotoxin was demonstrated. In a similar group of experiments to those described (Figure 5 ). In a second specificity experiment an attempt was made to block the binding of the HB2-Sap immunotoxin to HSB-2 cells by incubating in the presence of increasing concentrations of the native anti-CD7 antibody HB2. HSB-2 cells were exposed for 48 h to a fixed concentration of HB2-Sap immunotoxin (10-9 M) in the presence of increasing concentrations of HB2 antibody (10-" to 10-7 M), then [3H]leucine incorporation was determined. The resulting dose-response curve demonstrated that in the presence of 10-7 M HB2 the cytotoxic effect of the immunotoxin was almost completely abrogated ( Figure 6 ). The survival data for the animals are shown in Figure 7 . At the termination of the experiment at 150 days there had been five deaths in the immunotoxin-treated group of animals compared with nine deaths in the control group. Postmortem and histological examination of tissues from animals surviving 150 days failed to demonstrate any evidence of leukaemic infiltration. Using Mantel-Cox log-rank analysis the survival of immmunotoxin-treated animals was significantly greater than that of controls (X2 = 5.348, P = 0.021).
No difference in survival was observed between PBS control and BU12-Sap immunotoxin-treated animals (data not shown). Animals treated with monoclonal HB2 antibody alone had no overall prolongation in survival (X2 = 2.124, P = 0.145), however it was interesting to note that there was a delay in the time it took for animals to die compared with controls. This result was confirmed in subsequent experiments, and in addition identical survival curves were obtained with a mixture of free saporin and monoclonal HB2 antibody in an amount equivalent to the immunotoxin (data not shown). We assume that this may be due to the recognition and destruction of antibody-coated leukaemic cells by NK cells present in the SCID mice (Dorshkind et al., 1985) though this is conjecture and we have no experimental evidence for this.
Discussion
Our study has demonstrated that the intravenous administration of the human T-ALL cell line HSB-2 into SCID mice produces a disseminated pattern of disease that closely mimics the pattern of disease observed in humans with acute lymphoblastic leukaemia. We were able to show that the anti-CD7-saporin immunotoxin HB2-Sap exerted a selective and potent cytotoxic effect against CD7+ HSB-2 cells in vitro and that this also translated into a significant in vivo therapeutic effect in HSB-2-bearing SCID mice. Thus, there was a prolonged survival of HSB-2-bearing animals given a single 10 ig i.v. dose of HB2-Sap IT. The observation that human acute leukaemia cells can be engrafted into SCID mice to produce a pattern of disease with biological similarities to human leukaemia is an important advance in our ability to be able to observe and manipulate in vivo therapeutic interventions. In nude mouse experimental models of human leukaemia, localised growth of solid tumours occurs (Dillman et al., 1985) and only a limited degree of extrapolation is possible to the disseminated pattern of disease seen in humans. The nude mouse is therefore limited to the information it can provide with respect to the biology and therapy of human leukaemia. The hope is that the SCID mouse model will provide a tool to aid the closer understanding of the complex in vivo interactions involved in disease states such as this.
One potential role for the SCID mouse model of leukaemia is in the assessment of novel therapeutic approaches such as the use of targeted immunotherapy. In a previous study (Flavell et al., 1991) we showed that the ribosome-inactivating protein saporin has potent in vitro cytotoxicity when targeted with a bispecific antibody to the CD7 surface antigen of HSB-2 cells. In the present study we have clearly demonstrated the effective and selective in vitro, cytotoxicity of an immunotoxin constructed with the anti-CD7 monoclonal antibody HB2 and saporin. Other workers have described the potency of immunotoxins constructed with the plant toxin ricin and anti-CD7 monoclonal antibodies (Vallera et al., 1983; Myers et al., 1984; Fishwild et al., 1992) , and with the single-chain ribosome-inactivating protein pokeweed antiviral protein (PAP) (Ramakrishnan & Houston, 1984) . The immunotoxin described by Ramakrishnan and Houston (1984) was constructed with the anti-CD7 monoclonal antibody 3A1 and PAP, and when directed against HSB-2 cells in vitro gave an IC50 of 0.11 nM. Our immunotoxin HB2-Sap gave an IC50 of 4.5 pM, similar to the figure (6.7 pM) reported by Fishwild et al. (1992) .
Interpretation of cytotoxicity between different immunotoxins needs to be examined with caution however. There are a number of possible reasons as to why our anti-CD7-saporin IT HB2-Sap appears more potent than some of the other published anti-CD7 ITs constructed with different toxins. Firstly, it may be that the HSB-2 target cells used in our studies may be intrinsically more sensitive to the action of immunotoxins generally. Only by comparing all the other ITs directly with each other against the same target cell line can this issue be resolved. Also, antibody affinity and the locality of the epitope recognised by the antibody in the target molecule can have marked effects in immunotoxin potency (Youle & Neville, 1982) , and equally these considerations may be responsible for the observed differences in potency.
In previous studies in our laboratory utilising a bispecific antibody, one Fab arm of which was constructed with the same anti-CD7 antibody HB2 and the other Fab arm with an anti-saporin antibody (HB2 x DB7-18), the delivery of saporin to HSB-2 cells was less efficient with an achieved IC50 of 0.23 nM (expressed as the concentration of free saporin in the system) (Flavell et al., 1991) . The improved effectiveness of the HB2-Sap immunotoxin over the bispecific antibody HB2 x DB7-18 is probably because the bispecific antibody attaches to the cell surface univalently and therefore has a lower binding avidity and also does not cross-link adjacent CD7 molecules on the cell surface. In contrast, the immunotoxin having two intact Fab arms with the same anti-CD7 specificity will bind with high avidity and moreover will cross-link adjacent CD7 molecules, resulting in more efficient internalisation by receptor-mediated endocytosis.
The therapeutic use of ricin immunotoxins in T-cell leukaemia has been described in nude mouse models of localised tumour growth (Weil-Hilman et al., 1987; Leonard et al., 1988 ) and more recently Jansen et al. (1992b) have described the in vivo use of an anti-CD7 deglycosylated ricin A-chain immunotoxin DA7 in SCID mice bearing the CD7+ T-ALL cell line MT-ALL. In this experimental therapy model, SCID mice were injected intravenously with 5 x 107 MT-ALL cells. Eight days following tumour cell injection therapy animals were given five consecutive daily intraperitoneal injections of 10 ,g of DA7 immunotoxin. This study demonstrated a highly significant anti-leukaemic effect of the immunotoxin compared with control animals. Similar results have been demonstrated in a SCID murine model of pre-B ALL using an anti-CD19 pokeweed antiviral protein immunotoxin . In the present study we have clearly demonstrated a significant therapeutic effect of the HB2-Sap IT in SCID mice bearing the human T-ALL cell line HSB-2. Moreover, our therapy study utilised only a single O jig dose of IT given on day 8 following leukaemia cell injection, a time at which we have demonstrated that animals have established disease. This response compares with the other in vivo SCID studies described above in which multiple doses of IT therapy have been shown to achieve good therapeutic results. Also, in the study of Uckun et al. (1990) , since the immunotoxin therapy commenced 1 day after the leukaemic cell inoculum, it could be argued that insufficient time was allowed for the animals to develop leukaemia prior to treatment and that this may have influenced the responses demonstrated.
The highly selective and highly cytotoxic nature of immunotoxins makes them ideal potential candidates for improving the therapy of haematological malignancies such as acute leukaemias and lymphomas. To date, however, only a limited number of clinical data have been collected in the systemic application of immunotoxins in this field. The use of immunotoxins in purging the bone marrow of autologous transplantation patients with ALL has been extensively investigated and is quite widely used in clinical practice (Uckun et al., 1990) . The clinical systemic use of immunotoxins in haematological malignancy is much less well researched and centres around preliminary phase I data (Laurent et al., 1986; Vitetta et al., 1991; Grossbard et al., 1992; Uckun et al., 1992b) . Little useful clinical information on the likely efficacy of such treatment in humans therefore currently exists but is slowly accumulating. Future phase II and III trials will be necessary in order to determine the precise role, if any, immunotoxins may have in the advancement of therapy in haematological malignancy.
In conclusion therefore we have been able to demonstrate the widespread dissemination of human T-ALL in SCID mice producing a pattern of disease mimicking the natural history of acute lymphoblastic leukaemia in man. Such a model may have many potential uses in the investigation of therapeutic and pharmacokinetic studies and the research of new anti-leukaemic agents. Using this animal model we have been able to show a significant therapeutic effect from a single intravenous injection of a CD7/saporin immunotoxin. Our results support the hopes that such agents may play a useful future role in the clinical management of patients with T-ALL.
